Familial hypercholesterolaemia.

Area of Science:

• Genetics
• Cardiology
• Metabolic Disorders

Background:

• Familial hypercholesterolaemia (FH) is a prevalent genetic disorder characterized by elevated low-density lipoprotein (LDL) cholesterol from birth.
• This condition significantly increases the risk of premature cardiovascular disease (CVD).
• Causative mutations typically occur in the LDLR gene, but APOB and PCSK9 gene mutations are also implicated.

Purpose of the Study:

• To provide an overview of familial hypercholesterolaemia, including its genetic basis, diagnosis, and management.
• To emphasize the importance of early detection and lifelong treatment for improving patient outcomes.
• To highlight the role of genetic testing and cascade screening in managing FH.

Main Methods:

• Review of diagnostic criteria for FH, including LDL cholesterol levels and family history.
• Discussion of genetic mutations (LDLR, APOB, PCSK9) underlying the disorder.
• Exploration of diagnostic approaches, including DNA-based methods and cascade screening.

Main Results:

• FH diagnosis relies on elevated LDL cholesterol and family history, with genetic testing aiding confirmation.
• Clinical severity is influenced by the specific gene mutation and its type.
• Lifelong LDL cholesterol-lowering treatment significantly enhances CVD-free survival.

Conclusions:

• Familial hypercholesterolaemia requires lifelong management with therapies like statins, ezetimibe, and PCSK9 inhibitors.
• Early diagnosis through cascade screening is vital for preventing premature cardiovascular events.
• Understanding the genetic basis of FH is key to effective diagnosis and personalized treatment strategies.